Proteomic profiling to predict therapeutic response to anti-PD1 therapy in advanced melanoma – SWATH MS dataset - glycopeptides

MS-based proteomics based on data-independent acquisition / SWATH MS was used to study the response of melanoma patients to anti-PD1 therapy. Human serum samples were collected from patients at the start of their therapy and later categorized into responders and non-responders based on clinical outcome. Samples were subjected to glycocapture and glycopeptides were quantified by SWATH MS followed by analysis using mapDIA to protein levels.